OBI.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 17:57):

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally...

Stats
Dzisiejszy wolumen	171 096
Średni wolumen	308 867
Kapitalizacja rynkowa	10.35M
EPS	£-0.124 ( 2011-06-30 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.880
ATR14	£0.199 (3.75%)

Ondine Biomedical Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ondine Biomedical Inc. Finanse

Annual	2022
Przychody:	£638 000
Zysk brutto:	£287 000 (44.98 %)
EPS:	£-0.110

FY	2022
Przychody:	£638 000
Zysk brutto:	£287 000 (44.98 %)
EPS:	£-0.110

FY	2021
Przychody:	£2.57M
Zysk brutto:	£1.25M (48.81 %)
EPS:	£-0.257

FY	2020
Przychody:	£1.79M
Zysk brutto:	£649 000 (36.24 %)
EPS:	£-0.0833

Financial Reports:

No articles found.

Ondine Biomedical Inc.

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.